192574-28-0

Basic information

• Product Name: 5-METHOXYCARBONYL-4-METHOXYMETHYL-1,2,3,6-TETRAHYDRO-2-OXO-6-(3,4-DIFLUOROPHENYL)PYRIMIDINE
• Synonyms: 5-METHOXYCARBONYL-4-METHOXYMETHYL-1,2,3,6-TETRAHYDRO-2-OXO-6-(3,4-DIFLUOROPHENYL)PYRIMIDINE;4-(3,4-DIFLUORO-PHENYL)-6-METHOXYMETHYL-2-OXO-1,2,3,4-TETRAHYDRO-PYRIMIDINE-5-CARBOXYLIC ACID METHYL ESTER(WX150121);4-(3,4-DIFLUORO-PHENYL)-6-METHOXYMETHYL-2-OXO-1,2,3,4-TETRAHYDRO-PYRIMIDINE-5-CARBOXYLIC ACID METHYL ESTER
• CAS NO: 192574-28-0
• Molecular Formula: C₁₄H₁₄F₂N₂O₄
• Molecular Weight: 312.27
• Mol File: 192574-28-0.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-METHOXYCARBONYL-4-METHOXYMETHYL-1,2,3,6-TETRAHYDRO-2-OXO-6-(3,4-DIFLUOROPHENYL)PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHOXYCARBONYL-4-METHOXYMETHYL-1,2,3,6-TETRAHYDRO-2-OXO-6-(3,4-DIFLUOROPHENYL)PYRIMIDINE(192574-28-0)
• EPA Substance Registry System: 5-METHOXYCARBONYL-4-METHOXYMETHYL-1,2,3,6-TETRAHYDRO-2-OXO-6-(3,4-DIFLUOROPHENYL)PYRIMIDINE(192574-28-0)

Safety Data

• Hazardous Substances Data: 192574-28-0(Hazardous Substances Data)

Upstream product

• 105025-71-6 methoxy acetoacetate 
• 34036-07-2 3,4 difluorobenzaldehyde 
• 497-19-8 sodium carbonate 
• 41051-15-4 4-methoxyacetoacetic acid methylester 
• 57-13-6 urea 

Downstream Products

• 218430-63-8 (S)-4-(3,4-difluorophenyl)-1,2,3,4-tetrahydro-6-(methoxymethyl)-2-oxo-5-pyrimidinecarboxylic acid methyl ester 
• 220497-99-4 (S)-4-(3,4-difluorophenyl)-1,2,3,4-tetrahydro-6-(methoxymethyl)-2-oxo-5-pyrimidinecarboxylic acid 
• 1571926-56-1 C₁₈H₂₀BrF₂N₃O₅ 

Relevant articles and documents

Efficient synthesis of the optically active dihydropyrimidinone of a potent α1A-selective adrenoceptor antagonist

The convergent synthesis of a potent α1A-selective adrenoceptor antagonist is described. Salient features of the synthesis include the enzymatic resolution of a racemic dihydropyrimidinone and the use of a palladium coupling reaction in the synthesis of 2,4′-dipyridyl.

DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof

This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors. This invention provides a method of modifying the feeding behavior of a subject which comprises administering to the subject an amount of an MCH1 antagonist effective to decrease the body mass of the subject and/or decrease the consumption of food by the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of an MCH1 antagonist effective to treat the subject's depression and/or anxiety.

Combination therapy for the treatment of benign prostatic hyperplasia

This invention relates to combination therapy for the treatment of benign prostatic hyperplasia comprising an alpha-1a antagonist and an endothelin antagonist. More specifically, the use of a selective alpha-1a adrenergic receptor antagonist in combination with a subtype non-selective endothelin antagonist provides relief of lower urinary tract symptoms in patients with symptomatic prostatism or benign prostatic hyperplasia. This combination therapy improves lower urinary tract symptoms including increasing urine flow rate, decreasing residual urine volume and improving overall obstructive and irritative symptoms in patients with benign prostatic hyperplasia or symptomatic prostatism.